tbuckley/cabot-search huggingface dataset:
High-precision tissue acquisition in the evaluation of breast microcalcifications.
Authors: J. Janssens, R. Harries, S. Lawson
Journal: Journal of Clinical Oncology (2010)

1567 Background: Clinical guidelines advocate the use of at least 6 cores with vacuum-assisted macrobiopsies in the evaluation of clusters of microcalcifications in the breast. In some centers the number of biopsies amount to 50 and more. However, multiple sampling has clinical limits since evaluation of surgical margins at surgery is difficult, resulting in an increased risk for multiple interventions, larger lumpectomies, and for mastectomy. Innovative novel biopsy instruments might decrease the number of biopsies while maintaining sensitivity and patient's comfort. Methods: 46 patients with a cluster of microcalcifications were selected to participate in this trial. A direct and frontal 10- gauge macrobiopsy system on an stereotactic upright mammography was used. The total number of samples (determined by the operator) and samples with microcalcifications. Patient satisfaction was scored from 1 (total comfort) to 5 (severe complaint) for pain, fear, and total experience. Results: The number of tissue samples with microcalcifications per number of total cores is tabulated (see Table). Sensitivity of the procedure was 98% and calcifications were detected in 107 out of 148 tissue specimen (73%). Patient satisfaction is high since average scores are under 3. Conclusions: The data suggest that a lower number of macrobiopsies for microcalcifications could be acceptable with direct and frontal biopsy methods without reducing sensitivity. Lowering the number of biopsies can optimize surgical margin interpretation and reduce the number of avoidable mastectomies. # of microcalcificationcontaining cores/total cores 1 core total 2 cores total 3 cores total 4 cores total 5 cores total 6 cores total 0 core with microcalcifications 1 1 core with microcalcifications 2 pts 2 1 1 2 cores with microcalcifications 11 10 1 1 3 cores with microcalcifications 4 2 2 4 cores with microcalcifications 4 2 5 cores with microcalcifications 1 6 cores with microcalcifications Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Abraxis BioScience, MedInvents MedInvents MedInvents
Serum Fatty Acid Binding Protein 4 (FABP4) Predicts Pre-eclampsia in Women With Type 1 Diabetes
Authors: Amy C. Wotherspoon, Ian S. Young, David R. McCance, Chris C. Patterson, Michael J.A. Maresh, Donald W.M. Pearson, James D. Walker, Valerie A. Holmes
Journal: Diabetes Care (2016)

To examine the association between fatty acid binding protein 4 (FABP4) and pre-eclampsia risk in women with type 1 diabetes.Serum FABP4 was measured in 710 women from the Diabetes and Pre-eclampsia Intervention Trial (DAPIT) in early pregnancy and in the second trimester (median 14 and 26 weeks' gestation, respectively).FABP4 was significantly elevated in early pregnancy (geometric mean 15.8 ng/mL [interquartile range 11.6-21.4] vs. 12.7 ng/mL [interquartile range 9.6-17]; P < 0.001) and the second trimester (18.8 ng/mL [interquartile range 13.6-25.8] vs. 14.6 ng/mL [interquartile range 10.8-19.7]; P < 0.001) in women in whom pre-eclampsia later developed. Elevated second-trimester FABP4 level was independently associated with pre-eclampsia (odds ratio 2.87 [95% CI 1.24-6.68], P = 0.03). The addition of FABP4 to established risk factors significantly improved net reclassification improvement at both time points and integrated discrimination improvement in the second trimester.Increased second-trimester FABP4 independently predicted pre-eclampsia and significantly improved reclassification and discrimination. FABP4 shows potential as a novel biomarker for pre-eclampsia prediction in women with type 1 diabetes.
Survival outcomes of schirrhus gastric cancer treated by multidisciplinary treatments: Putative impact on prognosis by DCS NAC.
Authors: Keishi Yamashita, Kei Hosoda, Natsuya Katada, Hiromitsu Moriya, Hiroaki Mieno, Shiro Kikuchi, Masahiko Watanabe
Journal: Journal of Clinical Oncology (2014)

128 Background: Among gastric cancer, schirrhus exhibited the poorest prognosis, and many patients die even after curative resection due to recurrence. Although progress of multidisciplinary treatments of advanced gastric cancer is outstanding, recent clinical outcome is obscure by such intensive treatments. Methods: Among the 5,664 gastric cancer patients who underwent gastrectomy between 1971 and 2013 in the Kitasato University Hospital, 287 of shirrhus gastric cancer were included (5%). We divided the total periods into early (1971-2004) and late period (2005-2013), and compared their prognosis. Multivariate proportional hazard model was applied to the significant univariate prognostic factors (p&lt;0.05), and identified independent prognostic factors (IPFs). Finally we compared the IPFs in terms of periods, and discuss the most appropriate treatments. Results: (1) Five-year survival rate was 13% and 31% in the early and late periods, respectively (p=0.0010). Between the periods, there were significant differences of pT (p=0.013), CY (p&lt;0.0001), and Margin status (p=0.041). (2) Univariate prognostic factors were age (p=0.032), pT (p=0.0009), pN (p&lt;0.0001), P (p=0.0033), CY (p=0.0002), and Margin status (p&lt;0.0001). Multivariate proportional hazard model elucidated IPFs of pN (pN0-2 vs pN3a-X, p&lt;0.0001) and Margin status (positive vs negative, p=0.0003). If the 2 factors were combined, patients with pN0-2 plus margin negative showed much better survival (about 40% of 5-year OS) than otherwise cases (below 10%)(p&lt;0.0001). (3) Comparison of the IPFs between early and late periods, margin positive cases were significantly less infrequent in the late period. This may be aggressive application of neoadjuvant chemotherapy of DCS (Docetaxel/CDDP/S1). Conclusions: Due to recent progress of multidisciplinary treatments of preoperative aggressive chemotherapy and surgery with curative intent for negative margin for schirrhus gastric cancer, its 5-year survival was dramatically improved. pN0-2 patients were promising for reasonable prognosis if negative margin is secured, so intraoperative diagnosis must be urgently developed.
Mitogen-Activated Protein Kinase 14 Promotes AKI
Authors: Alberto Ortiz, Holger Husi, Laura Gonzalez-Lafuente, Lara Valiño-Rivas, Manuel Fresno, Ana Belen Sanz, William Mullen, Amaya Albalat, Sergio Mezzano, Tonia Vlahou, Harald Mischak, Maria Dolores Sanchez-Niño
Journal: Journal of the American Society of Nephrology (2016)

An improved understanding of pathogenic pathways in AKI may identify novel therapeutic approaches. Previously, we conducted unbiased liquid chromatography-tandem mass spectrometry–based protein expression profiling of the renal proteome in mice with acute folate nephropathy. Here, analysis of the dataset identified enrichment of pathways involving NF κ B in the kidney cortex, and a targeted data mining approach identified components of the noncanonical NF κ B pathway, including the upstream kinase mitogen-activated protein kinase kinase kinase 14 (MAP3K14), the NF κ B DNA binding heterodimer RelB/NF κ B2, and proteins involved in NF κ B2 p100 ubiquitination and proteasomal processing to p52, as upregulated. Immunohistochemistry localized MAP3K14 expression to tubular cells in acute folate nephropathy and human AKI. In vivo , kidney expression levels of NF κ B2 p100 and p52 increased rapidly after folic acid injection, as did DNA binding of RelB and NF κ B2, detected in nuclei isolated from the kidneys. Compared with wild-type mice, MAP3K14 activity–deficient aly/aly (MAP3K14 aly/aly ) mice had less kidney dysfunction, inflammation, and apoptosis in acute folate nephropathy and less kidney dysfunction and a lower mortality rate in cisplatin-induced AKI. The exchange of bone marrow between wild-type and MAP3K14 aly/aly mice did not affect the survival rate of either group after folic acid injection. In cultured tubular cells, MAP3K14 small interfering RNA targeting decreased inflammation and cell death. Additionally, cell culture and in vivo studies identified the chemokines MCP-1, RANTES, and CXCL10 as MAP3K14 targets in tubular cells. In conclusion, MAP3K14 promotes kidney injury through promotion of inflammation and cell death and is a promising novel therapeutic target.
A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis
Authors: Dae Hyun Yoo, Chang-Hee Suh, Seung Cheol Shim, Slawomir Jeka, Francisco Fidencio Cons-Molina, Pawel Hrycaj, Piotr Wiland, Eun Young Lee, Francisco G Medina-Rodriguez, Pavel Shesternya, Sebastiao Radominski, Marina Stanislav, Volodymyr Kovalenko, Dong Hyuk Sheen, Leysan Myasoutova, Mie Jin Lim, Jung-Yoon Choe, Sang Joon Lee, Sung Young Lee, Taek Sang Kwon, Won Park
Journal: Annals of the Rheumatic Diseases (2016)

Objective To demonstrate pharmacokinetic equivalence of CT-P10 and innovator rituximab (RTX) in patients with rheumatoid arthritis (RA) with inadequate responses or intolerances to antitumour necrosis factor agents. Methods In this randomised phase I trial, patients with active RA were randomly assigned (2:1) to receive 1000 mg CT-P10 or RTX at weeks 0 and 2 (alongside continued methotrexate therapy). Primary endpoints were area under the serum concentration–time curve from time zero to last quantifiable concentration (AUC 0–last ) and maximum serum concentration after second infusion (C max ). Additional pharmacokinetic parameters, efficacy, pharmacodynamics, immunogenicity and safety were also assessed. Data are reported up to week 24. Results 103 patients were assigned to CT-P10 and 51 to RTX. The 90% CIs for the ratio of geometric means (CT-P10/RTX) for both primary endpoints were within the bioequivalence range of 80%–125% (AUC 0–last : 97.7% (90% CI 89.2% to 107.0%); C max : 97.6% (90% CI 92.0% to 103.5%)). Pharmacodynamics and efficacy were comparable between groups. Antidrug antibodies were detected in 17.6% of patients in each group at week 24. CT-P10 and RTX displayed similar safety profiles. Conclusions CT-P10 and RTX demonstrated equivalent pharmacokinetics and comparable efficacy, pharmacodynamics, immunogenicity and safety. Trial registration number NCT01534884.
Cancer Moonshot Stalls on the Launch Pad
Authors: Jeff Lyon
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Implementation of a National Semen Testing and Counseling Program for Male Ebola Survivors — Liberia, 2015–2016
Authors: Lawrence J. Purpura, Moses Soka, April Baller, Stephen White, Emerson Rogers, Mary J. Choi, Nuha Mahmoud, Christine Wasunna, Moses Massaquoi, Kristin Vanderende, Jomah Kollie, Straker Dweh, Philip Bemah, Athalia Christie, Victor Ladele, Onyekachi Subah, Satish Pillai, Margaret Mugisha, Jonathan Kpaka, Stuart Nichol, Ute Ströher, Neetu Abad, Shauna Mettee-Zarecki, Jeff A. Bailey, Pierre Rollin, Barbara Marston, Tolbert Nyenswah, Alex Gasasira, Barbara Knust, Desmond Williams
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

According to World Health Organization (WHO) data, the Ebola virus disease (Ebola) outbreak that began in West Africa in 2014 has resulted in 28,603 cases and 11,301 deaths (1). In March 2015, epidemiologic investigation and genetic sequencing in Liberia implicated sexual transmission from a male Ebola survivor, with Ebola virus detected by reverse transcription-polymerase chain reaction (RT-PCR) 199 days after symptom onset (2,3), far exceeding the 101 days reported from an earlier Ebola outbreak (4). In response, WHO released interim guidelines recommending that all male survivors, in addition to receiving condoms and sexual risk reduction counseling at discharge from an Ebola treatment unit (ETU), be offered semen testing for Ebola virus RNA by RT-PCR 3 months after disease onset, and every month thereafter until two consecutive semen specimens collected at least 1 week apart test negative for Ebola virus RNA (5). Male Ebola survivors should also receive counseling to promote safe sexual practices until their semen twice tests negative. When these recommendations were released, testing of semen was not widely available in Liberia. Challenges in establishing and operating the first nationwide semen testing and counseling program for male Ebola survivors included securing sufficient resources for the program, managing a public health semen testing program in the context of ongoing research studies that were also collecting and screening semen, identification of adequate numbers of trained counselors and appropriate health communication messages for the program, overcoming Ebola survivor-associated stigma, identification and recruitment of male Ebola survivors, and operation of mobile teams.
Structural pathology is not related to patient-reported pain and function in patients undergoing meniscal surgery
Authors: Simon Maretti Tornbjerg, Nis Nissen, Martin Englund, Uffe Jørgensen, Jeppe Schjerning, L Stefan Lohmander, Jonas Bloch Thorlund
Journal: British Journal of Sports Medicine (2016)

Background The relationship between meniscal tears and other joint pathologies with patient-reported symptoms is not clear. We investigated associations between structural knee pathologies identified at surgery with preoperative knee pain and function in patients undergoing arthroscopic meniscal surgery. Methods This study included 443 patients from the Knee Arthroscopy Cohort Southern Denmark (KACS), a prospective cohort following patients 18 years or older undergoing arthroscopic meniscal surgery at 4 hospitals between 1 February 2013 and 31 January 2014. Patient-reported outcomes, including the Knee Injury and Osteoarthritis Outcome Score (KOOS), were obtained by online questionnaires prior to surgery. Knee pathology was assessed by the operating surgeons using a modified version of the International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine (ISAKOS) classification of meniscal tears questionnaire, supplemented with information extracted from surgery reports. Following hypothesis-driven preselection of candidate variables, backward elimination regressions were performed to investigate associations between patient-reported outcomes and structural knee pathologies. Results Regression models only explained a small proportion of the variability in self-reported pain and function (adjusted R 2 =0.10−0.12) and this association was mainly driven by age, gender and body mass index. Conclusions Specific meniscal pathology and other structural joint pathologies found at meniscal surgery were not associated with preoperative self-reported pain and function in patients with meniscal tears questioning inferences made about a direct relationship between these. Our findings question the role of arthroscopic surgery to address structural pathology as a means to improve patient-reported outcomes in patients having surgery for a meniscal tear.
Fludarabine Phosphate-Based Nonmyeloablative Stem Cell Transplantation in the Elderly Patients: A BHS Study.
Authors: Dominique Bron, Pierre Zachée, Johan Maertens, Koen Theunissen, Augustin Ferrant, Philippe Martiat, Chantal Doyen, Luc Noens, Wilfried Schroyens, Dominique Sellesslag, Hilde Demuynck, Rick Schots, Anne De Meuter, Marc Boogaerts
Journal: Blood (2004)
La gestion des fièvres hémorragiques virales en Suisse
Authors: Stéphane Hugonnet, Hugo Sax, Didier Pittet
Journal: Eurosurveillance (2002)

La Suisse a connu tres peu de cas importes de fievre hemorragique virale (FHV) ces dernieres annees : un cas confirme et quatre suspects de fievre Ebola a Bâle en 1994, deux cas suspects de fievre Ebola et de Lassa a Lausanne en 2000, et la meme annee, si
Gut microbiota, metabolome and immune signatures in patients with uncomplicated diverticular disease
Authors: Giovanni Barbara, Eleonora Scaioli, Maria Raffaella Barbaro, Elena Biagi, Luca Laghi, Cesare Cremon, Giovanni Marasco, Antonio Colecchia, Gianfranco Picone, Nunzio Salfi, Francesco Capozzi, Patrizia Brigidi, Davide Festi
Journal: Gut (2016)

Objective The engagement of the gut microbiota in the development of symptoms and complications of diverticular disease has been frequently hypothesised. Our aim was to explore colonic immunocytes, gut microbiota and the metabolome in patients with diverticular disease in a descriptive, cross-sectional, pilot study. Design Following colonoscopy with biopsy and questionnaire phenotyping, patients were classified into diverticulosis or symptomatic uncomplicated diverticular disease; asymptomatic subjects served as controls. Mucosal immunocytes, in the diverticular region and in unaffected sites, were quantified with immunohistochemistry. Mucosa and faecal microbiota were analysed by the phylogenetic platform high taxonomic fingerprint (HTF)-Microbi.Array, while the metabolome was assessed by 1 H nuclear magnetic resonance. Results Compared with controls, patients with diverticula, regardless of symptoms, had a &gt;70% increase in colonic macrophages. Their faecal microbiota showed depletion of Clostridium cluster IV. Clostridium cluster IX, Fusobacterium and Lactobacillaceae were reduced in symptomatic versus asymptomatic patients. A negative correlation was found between macrophages and mucosal Clostridium cluster IV and Akkermansia . Urinary and faecal metabolome changes in diverticular disease involved the hippurate and kynurenine pathways. Six urinary molecules allowed to discriminate diverticular disease and control groups with &gt;95% accuracy. Conclusions Patients with colonic diverticular disease show depletion of microbiota members with anti-inflammatory activity associated with mucosal macrophage infiltration. Metabolome profiles were linked to inflammatory pathways and gut neuromotor dysfunction and showed the ability to discriminate diverticular subgroups and controls. These data pave the way for further large-scale studies specifically aimed at identifying microbiota signatures with a potential diagnostic value in patients with diverticular disease.
P2-270: Docetaxel monotherapy in second-line treatment in pretreated advanced non-small cell lung cancer (NSCLC) patients
Authors: Yoon Ho Ko, Kyo Young Lee, Myung Ah Lee, Yeong Seon Hong, Kyung Shik Lee, Yeon Sil Kim, Young Kyoon Kim, Young Pil Wang, Jin Hyoung Kang
Journal: Journal of Thoracic Oncology (2007)
Going Beyond Classic Descriptions to Future Phenomenology of Schizophrenia
Authors: Manuel J. Cuesta, Victor Peralta
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Successful application of endoscopic ultrasound-guided fine needle biopsy to establish pancreatic patient-derived tumor xenografts: a pilot study
Authors: Els Hermans, Schalk Van der Merwe, Jeroen Depreeuw, Jeroen Dekervel, Enrico Radaelli, Tania Roskams, Jos van Pelt Jos, Baki Topal, Chris Verslype, Hans Prenen, Werner Van Steenbergen, Frederik Nevens, Diether Lambrechts, Frédéric Amant
Journal: Endoscopy (2016)

Background and study aim: Typically, pancreatic patient-derived tumor xenografts (PDXs) are established by transplanting large tumor biopsies obtained through invasive surgery approaches into immunocompromised mice. We aimed to develop pancreatic PDXs by transplanting tumor tissue acquired by endoscopic ultrasound (EUS)-guided fine needle biopsies (FNB), assess take rates compared to surgery-derived PDXs, and demonstrate the histological and genetic resemblance to the original tumor. Patients and methods: Biopsies of untreated pancreatic carcinoma were collected at surgery and during EUS and processed to generate PDXs. Results: By centrifugation of FNB-derived tissue prior to engraftment, we achieved an engraftment rate of 60 % (6/10). Despite a decrease in stromal tissue, the general morphology of FNB-derived PDXs was conserved as assessed by histopathology. At the genetic level, somatic mutation and copy number profiles were largely similar to the primary tumor. Conclusion: We show that it is technically feasible to establish pancreatic PDXs using a minimally invasive sampling technique, such as EUS-FNB. Although only a limited amount of tumor tissue was acquired, we obtained results similar to those from surgery-derived PDXs.
Are AClonal@ X-chromosome inactivation patterns of T cells in MDS dependent on disease duration ? Evaluation of 117 patients with MDS
Authors: A Kündgen, M Aivado, A Rong, J Van Dijk, Michel Delforge, Anne Hagemeijer-Hausman, M Jotterand-Bellomo, I Tigaud, A Giagounidis, M Stadler, C Strupp, N Gatterman, R Haas, T de Witte, U Germng
Journal: Blood (2001)
P3-094: An expanded access clinical program of erlotinib (Tarceva™) in patients with advanced stage IIIB/ IV non-small cell lung cancer
Authors: Ming-Shyan Huang, Chih-Yuan Chung, Chao-Jung Tsao, Chang-Fang Chiu, Tsu-Yi Chao, Wu-Chou Su, Ruay-Sheng Lai, Nei-Min Chu, Ruey-Kuen Hsieh, Chen Yuh-Min
Journal: Journal of Thoracic Oncology (2007)
Exercise for the primary prevention of low back pain
Authors: Rahman Shiri
Journal: British Journal of Sports Medicine (2016)

The effect of exercise on primary prevention of low back pain (LBP) is uncertain. Saragiotto and Latimer1 summarised a recent meta-analysis of eight randomised controlled trials (RCTs, 11 reports) by Steffens et al .2 I have several major concerns regarding that meta-analysis.2

First, primary studies were incompletely identified using an inappropriate search strategy and symbols. Neither Embase nor the Cochrane Library uses a dollar sign ($), but an asterisk (*) as a truncation symbol to search for one or more missing characters. The authors2 identified 3.2 times more publications in Embase than in MEDLINE, and only …